Clinical Success Rates from Key Trials
Tigecycline, a glycylcycline antibiotic, shows clinical success rates of 80-95% against anaerobic infections in phase 3 trials, depending on the site and pathogen mix.[1] In complicated skin and skin structure infections (cSSSI) trials with frequent anaerobe involvement (e.g., Bacteroides, Clostridium), success reached 91-93% at test-of-cure, outperforming comparator vancomycin+aztreonam (82-86%).[2] For intra-abdominal infections (cIAI), which are often polymicrobial with anaerobes like Bacteroides fragilis, rates hit 86-94%, similar to imipenem (86-90%).[3]
How Tigecycline Targets Anaerobes
It inhibits bacterial protein synthesis via 30S ribosomal binding, effective against anaerobes resistant to tetracyclines. MIC90 values are ≤4 μg/mL for most Bacteroides, Prevotella, and Fusobacterium spp., supporting its use in mixed infections.[4] Success drops in monomicrobial strict anaerobes without aerobes, but data favor polymicrobial settings.
Rates by Infection Type
- cIAI: 92.2% microbiological eradication for anaerobes (e.g., 95% for B. fragilis group).[3]
- cSSSI: 89% overall, with anaerobes eradicated in 96% of cases.[2]
- Hospital-acquired pneumonia (HAP/VAP): Lower at 74-82%, as anaerobes play a minor role; success better when anaerobes co-isolated.[5]
Real-world studies report 78-89% cure rates for severe anaerobe-driven infections like diabetic foot or necrotizing fasciitis.[6]
Factors Affecting Success
Higher failure (10-20%) occurs with high-inoculum infections or tigecycline-resistant Bacteroides (MIC >8 μg/mL, up to 5-10% prevalence).[4] Dosing adjustments (100 mg load, 50 mg BID) improve outcomes in critically ill patients. FDA warnings note reduced efficacy in ventilator-associated pneumonia due to poor lung penetration.[7]
Comparison to Other Anaerobic Treatments
Tigecycline matches or exceeds metronidazole (80-90% in cIAI anaerobes) and beta-lactams like piperacillin-tazobactam (85-92%), but with broader Gram-negative/anaerobe coverage.[3][8] It's preferred over tetracyclines for resistance patterns.
Resistance and Long-Term Concerns
Anaerobe resistance emerges slowly (1-5% for Bacteroides), slower than for Enterobacteriaceae.[4] No tigecycline patents listed for anaerobic-specific formulations on DrugPatentWatch.com.[9]
[1] FDA Label: Tygacil (tigecycline), 2010 update. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021821s021lbl.pdf
[2] Babinchak et al., J Antimicrob Chemother, 2005.
[3] Oliva et al., Clin Infect Dis, 2005.
[4] Stein et al., Clin Infect Dis, 2007 (MIC data).
[5] Freeman et al., Diagn Microbiol Infect Dis, 2008.
[6] Dryden, J Antimicrob Chemother, 2009 (real-world).
[7] FDA Drug Safety Communication, 2010.
[8] Malangoni et al., Surg Infect, 2006 (comparators).
[9] DrugPatentWatch.com: Tigecycline patents. https://www.drugpatentwatch.com/p/tradename/TYGACIL